S1PR2 and myocardial infarction: The myocardial infarct size as a percentage of the area at risk was significantly smaller in the S1PR2 agonist group (14.2% ± 1.9%, n = 8) than in the Vehicle group (32.1% ± 5.5%, n = 8, p < 0.001) (Figure S4).